Enlightenment through smart measurements

Open menu

News & Events

OpSsens Will Participate and Present at Two Investment Conferences Lytham Partners and Raymond James

9 June 2021

OPSENS WILL PARTICIPATE AND PRESENT AT TWO INVESTMENT CONFERENCES Lytham Partners and Raymond James Quebec City, Quebec, June 9, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF),  a medical device cardiology-focused company commercializing a  second-generation fiber optic pressure guidewire to diagnose and treat coronary artery disease, announced today that it will present at…

Read more

OpSens to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference

13 May 2021

OpSens to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference Presentation at 11:30 a.m. ET on Wednesday, May 19, 2021 Quebec City, Quebec, May 13, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF),  a medical device cardiology-focused company commercializing a  second-generation fiber optic pressure guidewire to diagnose…

Read more

OPSENS INTEGRATES ITS OPTOWIRE’S dPR AND FFR ALGORITHMS WITHIN CATHMEDICAL CARDIOVASCULAR’S PICASSO SYSTEM IN SPAIN

21 April 2021

OpSens INTEGRATES ITS OPTOWIRE’S dPR AND FFR ALGORITHMS WITHIN CATHMEDICAL CARDIOVASCULAR’s PICASSO SYSTEM IN SPAIN Agreement Allows Cardiologists to Perform dPR and FFR Procedures Using OpSens’ OptoWire and Cathmedical’s Picasso System in an Integrated Fashion Quebec City, Quebec, April 21, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF),  a medical device cardiology-focused company, today announced…

Read more

OpSens Announces Q2 Fiscal 2021 Financial Results and Record FFR and dPR Revenues

14 April 2021

  OpSens Announces Q2 Fiscal 2021 Financial Results and Record FFR and dPR Revenues Quebec City, Quebec, April 14, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, today reported its financial results for the second quarter of fiscal…

Read more

OpSens AWARDED INNOVATIVE TECHNOLOGY CONTRACT BY VIZIENT FOR OPTOWIRE III

7 April 2021

OPSENS AWARDED INNOVATIVE TECHNOLOGY CONTRACT BY VIZIENT FOR OPTOWIRE III  Contract awarded for products that bring improvement to health care industry   Quebec City, Quebec, April 7, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company, announced today it has been awarded an Innovative Technology  contract from Vizient, Inc.,…

Read more

OpSens to Host Second Quarter Fiscal Year 2021 Financial Results Conference Call on Wednesday, April 14, 2021 – Conference call to be conducted at 11:00 am ET

6 April 2021

OpSens to Host Second Quarter Fiscal Year 2021 Financial Results Conference Call on Wednesday, April 14, 2021 Conference call to be conducted at 11:00 am ET Quebec City, Quebec, April 6, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical…

Read more

OpSens to Present at Lytham Partners Spring 2021 Investor Conference – Presentation at 9:30 a.m. ET on Tuesday, March 30, 2021

22 March 2021

OpSens to Present at Lytham Partners Spring 2021 Investor Conference Presentation at 9:30 a.m. ET on Tuesday, March 30, 2021 Quebec City, Quebec, March 22, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF),  a medical device cardiology-focused company commercializing a  second-generation fiber optic pressure guidewire to diagnose and treat coronary disease, announced today…

Read more

Article Journal de Québec – OpSens Médical: une technologie prometteuse qui ne tient qu’à un fil

1 March 2021

2021-02-28_JdeQ_OpSens Medical_une technologie prometteuse qui ne tient qua un fil

OpSens: Closing of $28.75 M Bought Deal Public Offering – Including $3.75 M Over-Allotment Option Exercised in Full

25 February 2021

OpSens Announces Closing of $28.75 M Bought Deal Public Offering Including $3.75 M Over-Allotment Option Exercised in Full   THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Quebec City, Canada, February 25, 2021 – OpSens Inc….

Read more

OpSens Obtains CE Marking for the OptoWire III

18 February 2021

OpSens Obtains CE Marking for the OptoWire III   Quebec City, Quebec, February 18, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company commercializing a second-generation fiber optic pressure guidewire to diagnose and treat coronary disease, has announced it has received CE marking for the OptoWire III, the latest…

Read more